126 related articles for article (PubMed ID: 34643153)
1. Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with acute myeloid leukemia meeting ineligibility criteria for high intensity chemotherapy.
Li S; Ji Y; Peng Y; Kota V; Kim C
Leuk Lymphoma; 2022 Jan; 63(1):131-141. PubMed ID: 34643153
[TBL] [Abstract][Full Text] [Related]
2. An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices.
Ma E; Bonthapally V; Chawla A; Lefebvre P; Swords R; Lafeuille MH; Fortier J; Emond B; Duh MS; Dezube BJ
Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):625-636.e3. PubMed ID: 27686689
[TBL] [Abstract][Full Text] [Related]
3. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
Meyers J; Yu Y; Kaye JA; Davis KL
Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
[TBL] [Abstract][Full Text] [Related]
4. [High-intensity chemotherapy versus palliative chemotherapy in patients over 60 years with acute myeloid leukemia].
Medrano-Contreras J; Talavera-Piña JO; Guerrero-Rivera S; Gutiérrez-Espíndola GR; Gómez-Cortés C; Pérez-Rocha JF; Terreros-Muñoz E; Meillón-García LA
Rev Med Inst Mex Seguro Soc; 2016; 54 Suppl 2():S148-55. PubMed ID: 27561018
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and a prognostic scoring system for elderly acute myeloid leukemia patients: a retrospective multicenter cohort study in China.
Zhang C; Wan W; Zhang S; Wang J; Feng R; Li J; Chai J; Zhou H; Wang L; Zhong Y; Mo X; Shen M; Jing H; Liu H
Cancer Biol Med; 2021 Aug; 19(6):871-83. PubMed ID: 34448555
[TBL] [Abstract][Full Text] [Related]
6. Elderly patients with acute myeloid leukemia who only receive supportive care in the Surveillance, Epidemiology and End Results-Medicare database: demographics, treatment patterns and outcomes.
Dharmani C; Wang E; Tu N; Fofah O; Cueto J; Salas M; Kamel YM
Future Oncol; 2023 Aug; 19(24):1677-1693. PubMed ID: 37345543
[TBL] [Abstract][Full Text] [Related]
7. Real-World Treatment Patterns and Clinical Outcomes in Korean Patients With AML Ineligible for First-Line Intensive Chemotherapy: A Subanalysis of the CURRENT Study, a Non-Interventional, Retrospective Chart Review.
Bang SM; Kang KW; Song IC; Llamas C; Duan Y; Jeong JY; Lee JH
J Korean Med Sci; 2023 Nov; 38(44):e345. PubMed ID: 37967874
[TBL] [Abstract][Full Text] [Related]
8. Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy
Miyamoto T; Sanford D; Tomuleasa C; Hsiao HH; Olivera LJE; Enjeti AK; Gimenez Conca A; Castillo TBD; Girshova L; Martelli MP; Guvenc B; Delgado A; Duan Y; Garbayo Guijarro B; Llamas C; Lee JH
Leuk Lymphoma; 2022 Apr; 63(4):928-938. PubMed ID: 35147482
[TBL] [Abstract][Full Text] [Related]
9. Treatment Pattern, Financial Burden, and Outcomes in Elderly Patients with Acute Myeloid Leukemia in Korea: A Nationwide Cohort Study.
Ha H; Jeong Y; Lim JH; Suh YJ
Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206499
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and outcomes of elderly patients with acute myeloid leukemia who receive no treatment in the Surveillance, Epidemiology and End Results-Medicare database.
Dharmani C; Wang E; Tu N; Salas M; Kamel YM
Future Oncol; 2023 Jan; 19(2):159-171. PubMed ID: 36912693
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
Boddu PC; Kantarjian HM; Ravandi F; Garcia-Manero G; Verstovsek S; Jabbour EJ; Takahashi K; Bhalla K; Konopleva M; DiNardo CD; Ohanian M; Pemmaraju N; Jain N; Pierce S; Wierda WG; Cortes JE; Kadia TM
Cancer; 2017 Aug; 123(16):3050-3060. PubMed ID: 28387922
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience.
Heiblig M; Le Jeune C; Elhamri M; Balsat M; Tigaud I; Plesa A; Barraco F; Labussière H; Ducastelle S; Nicolini F; Wattel E; Salles G; Thomas X
Leuk Lymphoma; 2017 Jan; 58(1):110-117. PubMed ID: 27184036
[TBL] [Abstract][Full Text] [Related]
14. Arsenic-Containing Qinghuang Powder () is an Alternative Treatment for Elderly Acute Myeloid Leukemia Patients Refusing Low-Intensity Chemotherapy.
Fan T; Quan RC; Liu WY; Xiao HY; Tang XD; Liu C; Li L; Lv Y; Wang HZ; Xu YG; Guo XQ; Hu XM
Chin J Integr Med; 2020 May; 26(5):339-344. PubMed ID: 31848890
[TBL] [Abstract][Full Text] [Related]
15. Outcome of patients aged 60-75 years with newly diagnosed secondary acute myeloid leukemia: A single-institution experience.
Bertoli S; Tavitian S; Bories P; Luquet I; Delabesse E; Comont T; Sarry A; Huguet F; Bérard E; Récher C
Cancer Med; 2019 Jul; 8(8):3846-3854. PubMed ID: 31173485
[TBL] [Abstract][Full Text] [Related]
16. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
17. Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia.
Wu YH; Xiao HY; Quan RC; Tang XD; Liu WY; Lyu Y; Chen Z; Liu C; Hu XM
Chin J Integr Med; 2023 Sep; 29(9):832-837. PubMed ID: 37222831
[TBL] [Abstract][Full Text] [Related]
18. Intensive chemotherapy in patients aged 70 years or older newly diagnosed with acute myeloid leukemia.
Ross K; Gillespie-Twardy AL; Agha M; Raptis A; Hou JZ; Farah R; Redner RL; Im A; Duggal S; Ding F; Lin Y; Boyiadzis M
Oncol Res; 2015; 22(2):85-92. PubMed ID: 25706395
[TBL] [Abstract][Full Text] [Related]
19. Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study.
Ito T; Sanford D; Tomuleasa C; Hsiao HH; Olivera LJE; Enjeti AK; Conca AG; Del Castillo TB; Girshova L; Martelli MP; Guvenc B; Bui CN; Delgado A; Duan Y; Guijarro BG; Llamas C; Lee JH
Eur J Haematol; 2022 Jul; 109(1):58-68. PubMed ID: 35298049
[TBL] [Abstract][Full Text] [Related]
20. Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia.
Talati C; Dhulipala VC; Extermann MT; Ali NA; Kim J; Komrokji R; Sweet K; Kuykendall A; Sehovic M; Reljic T; Djulbegovic B; Lancet JE
Haematologica; 2020; 105(2):398-406. PubMed ID: 31073071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
